Crispr Therapeutics Ag(CRSP-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low53.02
Day High55.79
Open:54.41
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year
Motley Fool
The Best Biotech Stocks to Buy in 2026
Motley Fool
Here's How I'd Invest $10,000 Right Now
Tipranks
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Hinge Health, Inc. Class A (HNGE)
Tipranks
Crispr Therapeutics AG (CRSP) Gets a Buy from Mizuho Securities
Motley Fool
CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus?
Tipranks
Shareholders Approve New Incentive Plan and Governance Measures
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: Insulet (PODD), Crispr Therapeutics AG (CRSP)
Motley Fool
CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential
Motley Fool
Eli Lilly Just Proved Gene Editing Could Be Pharma's Next Gold Rush -- but CRISPR Therapeutics Investors Should Watch Out
Motley Fool
CRISPR Therapeutics' Secret Weapon That Many Investors Are Overlooking
Motley Fool
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?
Motley Fool
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics?
Tipranks
Crispr Therapeutics Opens New Front in Cholesterol With CTX310 Trial
Motley Fool
The Best Stocks to Invest $3,000 In Right Now
MarketBeat
CRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data Looms
MarketBeat.com
Tipranks
Analysts Are Bullish on These Healthcare Stocks: Crispr Therapeutics AG (CRSP), Caris Life Sciences, Inc. (CAI)
Motley Fool
1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist?
Tipranks
Analysts Conflicted on These Healthcare Names: Dexcom (DXCM), Ironwood Pharma (IRWD) and Crispr Therapeutics AG (CRSP)

Profile

CRISPR Therapeutics AG is a leading gene editing company focused on developing CRISPR/Cas9-based therapeutics. The company is rapidly leveraging its CRISPR/Cas9 gene-editing platform to make therapies for the treatment of hemoglobinopathies, cancer, diabetes and other diseases.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.